Medicine Recommendations

This colour classification is in agreement with the recommendations contained within the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017

Adjunct treatment of seizures in Lennox-Gastaut syndrome

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products   

Treating symptomatic chronic heart failure with reduced ejection fraction (NICE TA388)

NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

Treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD medicinal products in mid to late stage fluctuating patients

Breathlessness

Rheumatoid arthritis (LSCMMG pathway)

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

For treating non-radiographic axial spondyloarthritis.

NICE TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis

Palmoplantar psoriasis

Moderate to Severe Plaque Psoriasis (NICE TA350)

NICE TA 350 - Secukinumab for treating moderate to severe plaque psoriasis

Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)

NICE TA407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)

NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; or in addition to other medicinal products for the treatment of diabetes.

NICE NG28 - Type 2 diabetes in adults: management

Managing overweight and obesity (NICE TA875)

NICE TA 875 - Semaglutide for managing overweight and obesity

For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise.

Constipation in children

Constipation

Opioid-induced constipation

Schizophrenia (not first line)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis

Use in patients being treated with anti-TNF biologics for Rheumatoid Arthritis